Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 3/20 | 0.55 |
| ▸ | AURKA | O14965 | 8/20 | 0.52 |
| ▸ | MET | P08581 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | FLT4 | P35916 | 1/20 | 0.49 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.48 |
| ▸ | TNNI3K | Q59H18 | 3/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL735116 | 0.88 | PTGS2 (0.70) | PTGS2KDRAURKAAURKBEGFR | |
| SCHEMBL757854 | 0.87 | PTGS2 (0.69) | PTGS2KDRAURKAAURKBEGFR | |
| SCHEMBL759953 | 0.87 | PTGS2 (0.69) | PTGS2KDRAURKAAURKBEGFR | |
| SCHEMBL759096 | 0.79 | MKNK1 (0.51) | PTGS2AURKAEGFR | |
| SCHEMBL757525 | 0.77 | EGFR (0.51) | PTGS2AURKAAURKBEGFR | |
| SCHEMBL759229 | 0.77 | TNNI3K (0.56) | PTGS2AURKAAURKBEGFRTNNI3K | |
| SCHEMBL759860 | 0.76 | AURKA (0.52) | PTGS2AURKAAURKBTNNI3K | |
| SCHEMBL759224 | 0.74 | EGFR (0.58) | AURKAAURKBEGFR | |
| SCHEMBL759223 | 0.72 | AURKA (0.67) | AURKAAURKB | |
| SCHEMBL13399828 | 0.72 | AURKA (0.60) | KDRAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2276346-B1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NAT HEALTH RESEARCH INSTITUTES (TW) | 2016-11-23 | — | — | EP | disclosed |
| US-8138194-B2 | Fused bicyclic pyrimidine compounds as aurora kinase inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2012-03-20 | — | — | US | disclosed |
| US-20090275533-A1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | US | disclosed |
| WO-2009134658-A2 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275533-A1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | AURKB, AURKA, AURKC | PTGS2 4714/4885KDR 1920/4885AURKA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.